Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.

ABSTRACT:

Objective

To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether sNfL reflects MS disease activity and disease-modifying therapy usage.

Methods

This was a post hoc analysis of longitudinal data and samples from the ADVANCE trial (NCT00906399) of patients with relapsing-remitting MS (RRMS). sNfL was measured every 3 months for 2 years, then every 6 months for 4 years. Regression models explored how sNfL data predicted 4-year values of brain volume, expanded disability status scale score, and T2 lesions. sNfL levels were assessed in those receiving placebo, peginterferon beta-1a, and those with disease activity.

Results

Baseline sNfL was a predictor of 4-

SUBMITTER: Calabresi PA 

PROVIDER: S-EPMC8414824 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature